Effects of 4-phenylbutyric acid on the process and development of diabetic nephropathy induced in rats by streptozotocin: regulation of endoplasmic reticulum stress-oxidative activation

Toxicol Appl Pharmacol. 2010 Jul;246(1-2):49-57. doi: 10.1016/j.taap.2010.04.005. Epub 2010 Apr 24.

Abstract

Oxidative stress may contribute to the pathogenesis of diabetic nephropathy (DN), although the precise regulatory mechanism is still unclear. Recent reports have shown that chemical molecular chaperone 4-phenylbutyric acid (4-PBA) can suppress oxidative stress by attenuating endoplasmic reticulum (ER) stress. We therefore hypothesized that 4-PBA could provide renoprotection through the suppression of oxidative stress in DN rats. Male Sprague-Dawley (SD) rats were randomly divided into three groups: a normal control (NC) group, a streptozotocin (STZ)-induced DN model group, and a DN plus 4-PBA (1g/kg) treatment group. At the end of 4, 8, and 12 weeks, hydroxyproline content, NADPH oxidase activity and the expression of phosphorylation of inositol-requiring enzyme-1alpha (p-IRE1alpha), p47phox, nitrotyrosine (NT) and NF-E2-related factor 2 (Nrf2) in the kidneys of all rats were determined; malondialdehyde (MDA) levels and superoxide dismutase (SOD) activity in serum and urine were also detected; renal nuclear factor kappaB (NF-kappaB) activity in all of the rats was examined at the end of 12 weeks. Compared with the NC group, the DN rats showed a significant increase in hydroxyproline content, NADPH oxidase activity, NF-kappaB activity, the expression of p-IRE1alpha, p47phox, NT and Nrf2 in renal tissue; markedly, MDA levels were higher and SOD activity was lower in serum and urine of DN rats than in NC rats for the indicated time. These alterations were inhibited by the administration of 4-PBA. These findings first demonstrated that treatment with 4-PBA significantly inhibits the process and development of diabetic nephropathy in rats through the regulation of ER stress-oxidative activation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use*
  • Blood Urea Nitrogen
  • Creatinine / blood
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetic Nephropathies / drug therapy*
  • Endoplasmic Reticulum / drug effects*
  • Endoplasmic Reticulum / metabolism
  • Hydroxyproline / analysis
  • Kidney / chemistry
  • Kidney / drug effects
  • Kidney / metabolism
  • Kidney / pathology
  • Male
  • Malondialdehyde / blood
  • Malondialdehyde / urine
  • NADPH Oxidases / metabolism
  • Oxidative Stress / drug effects*
  • Phenylbutyrates / pharmacology
  • Phenylbutyrates / therapeutic use*
  • Proteinuria / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Superoxide Dismutase / blood
  • Superoxide Dismutase / urine

Substances

  • Antioxidants
  • Phenylbutyrates
  • Malondialdehyde
  • 4-phenylbutyric acid
  • Creatinine
  • Superoxide Dismutase
  • NADPH Oxidases
  • Hydroxyproline